Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05769010

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

A Prospective, Open-label Explorative Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Henan Cancer Hospital · Other Government
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study aimed to evaluate the use of SHR-A1811 in HER2-expression Advanced Breast Cancer patients with brain metastases.

Conditions

Interventions

TypeNameDescription
DRUGSHR-A1811SHR-A1811: intravenous
DRUGPyrotinibPyrotinib: oral
DRUGBevacizumabBevacizumab: intravenous
DRUGAdebelizumabAdebelizumab: intravenous

Timeline

Start date
2023-03-31
Primary completion
2028-12-30
Completion
2029-06-30
First posted
2023-03-15
Last updated
2026-04-01

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05769010. Inclusion in this directory is not an endorsement.

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases (NCT05769010) · Clinical Trials Directory